SCHEMBL4056580

SCHEMBL4056580

CCOc1ccc(CCc2nc3ncc(Br)cc3[nH]2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS1 P29475 4/20 0.58
NOS2 P35228 4/20 0.58
NOS3 P29474 3/20 0.58
SMN1; SMN2 Q16637 3/20 0.52
NPSR1 Q6W5P4 3/20 0.52
RXFP1 Q9HBX9 2/20 0.52
LMNA P02545 1/20 0.52
HTT P42858 1/20 0.52
ALDH1A1 P00352 3/20 0.43
MAPK10 P53779 1/20 0.43
HPGD P15428 3/20 0.43
TDP1 Q9NUW8 2/20 0.43
POLB P06746 1/20 0.43
CTDSP1 Q9GZU7 1/20 0.43
PKM P14618 1/20 0.41
AURKA O14965 1/20 0.40
GPR84 Q9NQS5 1/20 0.40
CNR2 P34972 1/20 0.39
TBK1 Q9UHD2 1/20 0.38
CYP2C9 P11712 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4051806 0.91 NOS3 (0.56) NOS1NOS2NOS3SMN1; SMN2NPSR1
SCHEMBL4059153 0.89 NOS1 (0.69) NOS1NOS2NOS3SMN1; SMN2NPSR1
SCHEMBL4061756 0.86 NOS3 (0.56) NOS1NOS2NOS3SMN1; SMN2NPSR1
SCHEMBL4053617 0.85 NOS3 (0.57) NOS1NOS2NOS3SMN1; SMN2NPSR1
SCHEMBL4052894 0.82 NOS1 (0.61) NOS1NOS2NOS3SMN1; SMN2NPSR1
SCHEMBL4049425 0.82 HPGD (0.62) NOS1NOS2NOS3SMN1; SMN2NPSR1
SCHEMBL4053812 0.82 NOS3 (0.54) NOS1NOS2NOS3SMN1; SMN2NPSR1
SCHEMBL4051158 0.82 ALDH1A1 (0.57) NOS1NOS2NOS3SMN1; SMN2NPSR1
SCHEMBL4058885 0.81 NOS3 (0.51) NOS1NOS2NOS3SMN1; SMN2NPSR1
SCHEMBL4057108 0.81 NOS3 (0.54) NOS1NOS2NOS3SMN1; SMN2NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-20050101647-A1 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-12 US disclosed
EP-1460067-A1 BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Chemical Industries, Ltd. (JP) 2004-09-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101647-A1 Bicyclic derivative, its production and use ABL1, SRC, PTK2B NOS1 879/4885NOS2 1019/4885NOS3 907/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.